RESIST-2: 2nd-line ART for HIV-2 Infection

Stopped COVID-19 and Funding

Conditions

• HIV-2 Infection

Interventions

• DIAGNOSTIC_TEST: HIV-2 Genotypic Drug Resistance Testing using DBS
• DRUG: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)
• DRUG: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
• DRUG: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)

Sponsor

University of Washington

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]